POSTER PRESENTATIONS: Posters Saturday, 22 April 2017: Viral hepatitis: Hepatitis C – Clinical (therapy)SAT-280 - SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies
References (0)
Cited by (0)
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.